Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

e to MN-166 for the treatment of MS, excluding ophthalmic solution formulations, from Kyorin Pharmaceutical Co. Ltd. For the past 17 years, MN-166 has been marketed in Japan and South Korea as Ketas(r) for the treatment of asthma and cerebrovascular disorders. Data from the existing clinical trial and post-marketing surveillance databases, which includes treatment of an estimated 3.2 million patients with these disorders, indicate that Ketas(r) is well tolerated.

Conference Call

Management will discuss the results in a conference call on March 29, 2007 at 2:00 p.m. Pacific Time. The dial-in numbers for the conference call are as follows: 800-479-9001 (Domestic); 719-457-2618 (International).

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company that acquires well characterized small-molecule drugs through strategic alliances with Japanese and other international pharmaceutical companies and accelerates their development in a diversified portfolio of therapeutic product candidates targeting significant disease markets. MediciNova's pipeline, which includes six compounds in clinical testing, targets a variety of prevalent medical conditions, including asthma, multiple sclerosis, status asthmaticus, interstitial cystitis, cancer, Generalized Anxiety Disorder, insomnia, preterm labor, urinary incontinence and thrombotic disorders. For more information on MediciNova, Inc., please visit www.medicinova.com.

The MediciNova, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3135

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/26/2014)... 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of experience ... 1999. Prior to Ms. Zhang,s appointment as the Company,s ...
(Date:11/24/2014)... , Nov. 24, 2014 Juno Therapeutics ... Therapy Designation to the company,s JCAR015 chimeric antigen ... treatment of relapsed or refractory B-cell acute lymphoblastic ... Memorial Sloan Kettering Cancer Center, where Phase 1 ... "The FDA,s action is important news for patients ...
(Date:11/24/2014)... , Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced today that Sergio ... at the LD MICRO "MAIN Event" Micro-Cap Growth Conference ... held at the Luxe Sunset Bel Air Hotel, which ... Los Angeles, California . The presentation ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today ... the majority that Restanza(TM) (cethromycin) demonstrated safety for ... pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). ... efficacy in the treatment of CAP (3 positive, 11 ...
... June 2 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, today announced ... Biomedical Advanced Research and Development Authority (BARDA) in ... advanced research and development of medical countermeasures for ...
Cached Medicine Technology:Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 2Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 2PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 4PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 5
(Date:11/26/2014)... The city of San Diego, California, ... forward with a plan to recycle wastewater – also ... Kleyne supports the San Diego plan as part of ... to Kleyne, by recycling water that San Diego already ... be greatly reduced. (Spagat, E, “San Diego looks to ...
(Date:11/26/2014)... 2014 For its December issue ... AIS Report on Blue Cross and Blue Shield Plans* ... the varied strategies the two Blues plans are implementing ... treatments for sleep apnea, ranging from brick-and-mortar retail stores ... linked to increased rates of a variety of serious ...
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... With a redesign of the practice ... has enhanced the user experience and functionality of ... an online destination for orthopedic and sports medicine knowledge ... new and improved version of the website. The ... ever for current and prospective patients to find answers ...
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5
... Novel HIV Drug to be Studied in Cell ... A $6 million, five-year federal grant to The ... to investigate a novel approach in treating HIV infection ... therapies for psychological and neurological effects in AIDS. ...
... to concerns that the human papillomavirus vaccine might promote ... found that the majority of respondents did not believe ... infections. The study, conducted by University of Illinois ... and in the November issue of the Journal ...
... utter words , THURSDAY, Oct. 15 (HealthDay News) -- ... how the human brain computes language. , "Two central ... study: one, the way in which higher cognitive processes ... two, the nature of what is perhaps the best-known ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... ... the life science, engineering and entertainment industries, announced today they have signed an intellectual ... incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer of ...
... , NEW YORK, Oct. 15 The Nielsen Company ... CLIO Awards , one of the world,s most recognized international advertising ... "The Dr. Oz Show" and featured health expert ... Honorary CLIO Healthcare Award live at the first-ever CLIO Healthcare ...
Cached Medicine News:Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:UIC study finds girls aware of HPV vaccine's benefits 2Health News:Brain Yields Up Clues to Language 2Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 2Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 3